COVID-19相关心肌炎:系统综述
本系统综述旨在总结COVID-19相关心肌炎的临床表现、危险因素和预后。综述发现COVID-19患者原发性急性心衰有两种不同病因且发生率惊人地相等:病毒性心肌炎和Takotsubo心肌病。COVID心肌炎、Takotsubo心肌病和重症COVID-19在临床上无法区分,均可表现为呼吸困难和心脏损伤证据,但心肌炎和Takotsubo为原发性心脏功能障碍,而重症COVID-19为呼吸衰竭所致。结论指出COVID-19相关心肌炎以早期休克状态区别于COVID-19呼吸衰竭,但并非所有心衰均来自直接病毒感染;作者认为类固醇可能是有益的治疗,类似于其他危重COVID-19患者;COVID-19患者出现心电图改变或肌钙蛋白升高应促使医生考虑合并心肌炎。
要点
- COVID-19相关心肌炎以早期休克状态区别于COVID-19呼吸衰竭。
- COVID-19患者原发性急性心衰有两种病因且发生率惊人地相等:病毒性心肌炎和Takotsubo心肌病。
- COVID心肌炎、Takotsubo心肌病和重症COVID-19临床无法区分,均可表现为呼吸困难和心脏损伤证据。
- 作者认为类固醇可能是有益的治疗,类似于其他危重COVID-19患者。
- COVID-19患者出现心电图改变或肌钙蛋白升高应促使医生考虑合并心肌炎。
适用人群与场景
- COVID-19患者,包括出现原发性急性心脏衰竭或早期休克状态者。
处置流程与药物剂量
- 作者认为类固醇可能是有益的治疗,类似于其他危重COVID-19患者。
红旗征与不能漏的情况
- COVID-19患者出现心电图改变或肌钙蛋白升高应促使医生考虑合并心肌炎。
- COVID-19相关心肌炎以早期休克状态为特征,区别于COVID-19呼吸衰竭。
研究设计与关键结果
- 系统综述发现COVID-19患者原发性急性心衰有两种不同病因且发生率惊人地相等:病毒性心肌炎和Takotsubo心肌病。
- COVID心肌炎、Takotsubo心肌病和重症COVID-19临床无法区分,均可表现为呼吸困难和心脏损伤证据;心肌炎和Takotsubo为原发性心脏功能障碍,重症COVID-19为呼吸衰竭所致。
证据类型、等级与局限
- 证据类型:系统综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- COVID-19患者出现心电图改变或肌钙蛋白升高时,应促使医生考虑合并心肌炎。
- 作者认为类固醇可能是有益的治疗,类似于其他危重COVID-19患者。
- COVID-19相关心肌炎以早期休克状态区别于COVID-19呼吸衰竭;并非所有心衰均来自直接病毒感染,部分患者发生Takotsubo心肌病。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Most COVID-19 infections result in a viral syndrome characterized by fever, cough, shortness of breath, and myalgias. A small but significant proportion of patients develop severe COVID-19 resulting in respiratory failure. Many of these patients also develop multi-organ dysfunction as a byproduct of their critical illness. Although heart failure can be a part of this, there also appears to be a subset of patients who have primary cardiac collapse from COVID-19.
OBJECTIVE: Conduct a systematic review of COVID-19-associated myocarditis, including clinical presentation, risk factors, and prognosis.
DISCUSSION: Our review demonstrates two distinct etiologies of primary acute heart failure in surprisingly equal incidence in patients with COVID-19: viral myocarditis and Takotsubo cardiomyopathy. COVID myocarditis, Takotsubo cardiomyopathy, and severe COVID-19 can be clinically indistinguishable. All can present with dyspnea and evidence of cardiac injury, although in myocarditis and Takotsubo this is due to primary cardiac dysfunction as compared to respiratory failure in severe COVID-19.
CONCLUSION: COVID-19-associated myocarditis differs from COVID-19 respiratory failure by an early shock state. However, not all heart failure from COVID-19 is from direct viral infection; some patient's develop takotsubo cardiomyopathy. Regardless of etiology, steroids may be a beneficial treatment, similar to other critically ill COVID-19 patients. Evidence of cardiac injury in the form of ECG changes or elevated troponin in patients with COVID-19 should prompt providers to consider concurrent myocarditis.
参考来源
- Haussner W, DeRosa AP, Haussner D, et al. COVID-19 associated myocarditis: A systematic review. Am J Emerg Med. 2021. PMID: 34739868. doi:10.1016/j.ajem.2021.10.001
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。